Home  >  News
  Phase 3 VOYAGE 2 study of Tremfya demonstrates long-term skin clearance in patients with moderate-to-severe plaque psoriasis,   February 21, 2018
  Kancera announces positive results from phase I study of immunoregulating drug candidate KAND567,   February 21, 2018
  Phase 2 TB vaccine trial shows potential for new BCG revaccination strategies,   February 21, 2018
  Eli Lilly presents positive results from phase 3b trial of Taltz to treat genital psoriasis at AAD meeting,   February 20, 2018
  Novartis presents positive data from phase III SCALP study of Cosentyx in patients with scalp psoriasis at AAD annual meeting,   February 20, 2018
  Glenmark presents data from phase 2a study of GBR 830, an anti-OX40 monoclonal antibody to treat atopic dermatitis at AAD meeting,   February 20, 2018
  BerGenBio completes enrollment in phase II trial of selective AXL inhibitor bemcentinib in combo with Keytruda to treat advanced breast cancer,   February 20, 2018
  Sterna announces phase 2a study data of gata-3 specific DNAzyme formulation, sb012 in patients with ulcerative colitis,   February 20, 2018
  Avillion advances co-development programme with Merck; IND application open for phase 2 study of M1095 in plaque psoriasis,   February 19, 2018
  Evofem Biosciences completes enrollment of phase 3 clinical trial of amphora,   February 17, 2018
  Realm provides highlights of 2017 clinical trial performance and outlines 2018 milestones,   February 17, 2018
  Aravive begins phase 1 study of novel GAS6-AXL pathway inhibitor, AVB-S6-500 in US,   February 17, 2018
  SPINRAZA phase 3 study results published in individuals with later-onset spinal muscular atrophy,   February 16, 2018
  Verona Pharma provides update from clinical trials of RPL554 in COPD,   February 16, 2018
  Vertex announces positive phase 2 study of the NaV1.8 inhibitor VX-150 in patients with acute pain in bunionectomy surgery,   February 16, 2018
  Bicycle Therapeutics, Cancer Research UK announce initiation of first clinical study of a bicyclic peptide,   February 15, 2018
  Merck to discontinue APECS study evaluating verubecestat for treatment of prodromal alzheimer’s disease,   February 15, 2018
  Rexahn reports data from the ongoing phase 2a clinical trial of RX-3117 in advanced bladder cancer at the ASCO GU 2018 Annual Meeting,   February 14, 2018
  Intercept announces phase 3 reverse trial evaluating OCA for the treatment of NASH patients with compensated cirrhosis,   February 14, 2018
  Concert Pharmaceuticals announces initiation of enrollment in second cohort of CTP-543 phase 2a trial for alopecia areata,   February 14, 2018

Pharmabiz: PPM_150x60_2018
Copyright © 2016 Saffron Media Pvt. Ltd |